Clinical Trials Browser

Phase 1/2 × Multiple Myeloma × Vemurafenib × Clear all

NCT02115035 2014-08-27

A Single Agent Study to Evaluate the Overall Response Rate, Safety and Tolerability of Orally Administered Vemurafenib

Phase 1/2 Withdrawn

Multiple Myeloma